The regulatory landscape is evolving continuously as the use of new therapies grows and as new innovations come to light. Regulators want to support innovators to bring product to patients as quickly as possible and have developed a number of accelerated pathways to support this.


Today, regulators have created special regulatory designations, including provision for orphan drugs and regenerative medicine advanced therapy, often with fast-track pathways. We’ll help you navigate the right path for your product and deliver it to market, efficiently and effectively. Because we continuously monitor regulatory evolution we’ll help you access incentives or pathways that can accelerate and facilitate your development program.


Because we’re the whole package, we’ll get you there faster


However bold your ambitions, our deeply experienced experts know what it takes to navigate clinical and regulatory complexity and deliver new products to the market efficiently. Our combined understanding of the science as well as the clinical and regulatory path to commercialization means we spot the considerations and issues others might miss – ensuring that decisions now won’t cause delays later.

We can even take a leading role in regulatory agency meetings so that thinking is aligned and critical questions are answered ahead of time.


Get In Touch

Insights Hub

Sharing insights, questioning norms, asking the right questions - we'll never lose sight of what you're striving for. Our insight and expertise will help you bring the most innovative therapies within reach of patients around the world.
Placeholder Image

Cell & Gene Therapy: Maximizing Commercialization Potential

How to Navigate the Less Obvious Barriers to Brining Advanced & Highly Targeted Treatments to

Start a conversation today

If you’re developing something truly ground-breaking, Biopharma Excellence is the nearest resource you’ll find to someone who’s been there before.


    We are now Cencora PharmaLex 

    PharmaLex is now part of Cencora, a leading global healthcare company with a foundation in pharmaceutical distribution. In 2024 and beyond PharmaLex and all the companies in PharmaLex family will begin a journey to becoming Cencora as well. Cencora brings the companies and services together under one new name. The name will change, but the level of attention and service you receive remains the same.  

    Know more